ReviewMedical2026
From ancient remedy to modern use: cannabis and cannabinoids in cancer care in the United States.
Behl D.; Abrams D.; Zylla D.; D'Andre S. · Frontiers in oncology · 2026
Research summary
**Background & Methods**
This is a narrative review article examining the historical use and contemporary clinical application of cannabis and cannabinoids in cancer care within the United States. The review synthesizes evidence on the pharmacology, efficacy, safety, and regulatory status of cannabis compounds, particularly THC and CBD, across various cancer-related symptoms and treatment contexts.
**Key Findings**
• Synthetic cannabinoids are FDA-approved and have the strongest evidence base for managing chemotherapy-induced nausea and vomiting (CINV), with THC demonstrating the most robust clinical support among cannabis compounds.
• Evidence for cannabis efficacy in other cancer-related symptoms—including chemotherapy-induced peripheral neuropathy, insomnia, appetite stimulation, and non-neuropathic pain—remains limited, and CBD monotherapy has not demonstrated consistent or meaningful clinical benefit.
• While preclinical data suggest potential anti-cancer properties, no clinical evidence currently supports cannabis as a direct cancer treatment; cannabis may interact significantly with prescribed medications and immunotherapy effects are still under investigation.
**Dosage & Administration**
Not reported. The review does not specify dosing regimens or administration routes for cannabis or cannabinoid formulations in cancer populations.
**Safety & Adverse Effects**
Cannabis is generally well tolerated in cancer patients, though adverse effects can be significant. The review recommends cannabis use be discouraged in individuals under 25 years of age due to ongoing neurodevelopment. Patients with active psychiatric or cardiovascular conditions should use cannabis only under close clinical supervision. Significant drug interactions may occur, particularly with high-dose oral formulations that could affect medication metabolism and efficacy.
**Evidence Quality**
This narrative review is limited by its reliance on published literature without systematic review methodology or meta-analysis. The quality of evidence varies considerably across different symptom categories and cannabinoid types. Most cannabis research outside CINV management demonstrates limited or inconsistent evidence. The absence of large-scale randomized controlled trials for many indications restricts definitive conclusions. The rapidly evolving legal and regulatory landscape in the United States may affect research availability and generalizability. This review provides a comprehensive overview suitable for clinical decision-making but highlights significant evidence gaps requiring further rigorous investigation.
Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.
Journal
Frontiers in oncology
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed
More recent cannabis research
This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.